Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET

Company Participants

Andrew Faughnan - Executive Director-Investor Relations

John Crowley - Chairman and Chief Executive Officer

Bradley Campbell - President and Chief Operating Officer

Daphne Quimi - Chief Financial Officer

Jeffrey Castelli - Chief Development Officer

Conference Call Participants

Ritu Baral - Cowen

Anupam Rama - JPMorgan

Ellie Merle - UBS

Beth Feindt-Scott - SVB Leerink

Kristen Kluska - Cantor Fitzgerald

Dae Gon Ha - Stifel

Salveen Richter - Goldman Sachs

Yun Zhong - BTIG

Operator

Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics’ First Quarter 2022 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Executive Director of Investor Relations. You may begin.

Andrew Faughnan

Thank you, Charlotte. Good morning, everyone. Thank you for joining our conference call today to discuss Amicus Therapeutics’ first quarter 2022 financial results and corporate highlights.

Speaking on today’s call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A, we’ll have Dr. Mitchell Goldman, Chief Medical Officer; and Sébastien Martel, Chief Business Officer.

As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved. Any or all the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof.

For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and Risk Factors section of our Annual Report on our Form 10-K for the year ended 2021 and for the quarter ended March 31, 2022 to be filed later today with the Securities and Exchange Commission.